Objectives: To review the evidence-based management of nausea and vomiting of pregnancy (NVP) and hyperemesis gravidarum. Evidence: MEDLINE and Cochrane database searches were performed using the medical subject headings (MeSH) of treatment, nausea, vomiting, pregnancy, and hyperemesis gravidarum. The quality of evidence reported in these guidelines has been described using the Evaluation of Evidence criteria outlined in the Report of the Canadian Task Force on the Periodic Health Exam. Benefits: NVP has a profound effect on women's health and quality of life during pregnancy, as well as a financial impact on the health care system, and its early recognition and management are recommended. (III-B) Cost: Costs, including hospitalizations, additional office visits, and time lost from work, may be reduced if NVP is treated early. 
INTRODUCTION
Nausea and vomiting of pregnancy (NVP) is the most common medical condition in pregnancy, affecting 50%-90% of women. 1 The most severe form of NVP is commonly referred to as hyperemesis gravidarum (HG). HG, defined as persistent vomiting that leads to weight loss greater than 5% of pre-pregnancy weight, with associated electrolyte imbalance and ketonuria, 1 occurs in about 1% of pregnancies. 1 Although NVP may be classified as mild, moderate, or severe, the severity of nausea or vomiting may not adequately reflect the distress it causes.
The physical and emotional impact of NVP often results in feelings of anxiety and worry about the effect of the symptoms on the fetus. It has a negative impact on family relationships and has major consequences on women's working abilities; 47% of working women with NVP feel job efficiency is reduced, 3 35% lose work time (mean loss of 62 working hours per woman), 3 and 25% lose time from housework (mean loss of 32 hours per woman). [1] [2] [3] [4] NVP is also cited as a reason for elective termination of pregnancy. 5 This is not surprising when it is recognized that nausea experienced by pregnant women with NVP (excluding HG patients) is comparable in severity to the nausea experienced by patients undergoing cancer chemotherapy. 6 Each year, a significant number of women have one or more hospital admissions for NVP (as many as 14 hospitalizations/1000 births). 7 Therefore, early recognition and management of NVP could have a profound effect on women's health and quality of life during pregnancy, as well as a financial impact on the health care system.
The pathogenesis of NVP is poorly understood and the etiology is likely to be multifactorial. Other causes of nausea and vomiting must be ruled out, including gastrointestinal, genitourinary, central nervous system, and toxic/metabolic problems. Idiopathic NVP must be distinguished from NVP of known etiology, such as hydatidiform mole or multiple gestation.
In the aftermath of thalidomide and the voluntary withdrawal of Bendectin ® , pharmacological antiemetic therapy is still used with great caution by some patients and health care providers to treat NVP, and is erroneously considered to be contraindicated in pregnancy. 2 Care providers play a major role in counselling and reassuring patients on safe and effective treatments available for NVP. 2 This document aims to provide an evidence-based guideline to treat NVP. Early treatment with counselling is preferable, after appropriate history-taking and physical examinations have been done. Recognizing and treating NVP in a timely fashion will prevent the progression of NVP to HG and maternal complications, and reduce the risk of parenteral therapy and HG-related costs, including hospitalizations, additional office visits, and time lost from work. This should eventually result in improved maternal health and quality of life, as well as better family relationships.
The quality of evidence reported in these guidelines has been described using the Evaluation of Evidence criteria outlined in the Report of the Canadian Task Force on the Periodic Health Exam (Table) 
CLASSIFICATION OF RECOMMENDATIONS
Recommendations included in these guidelines have been adapted from the ranking method described in the Classification of Recommendations found in the Report of the Canadian Task Force on the Periodic Health Exam. A. There is good evidence to support the recommendation that the condition be specifically considered in a periodic health examination. B. There is fair evidence to support the recommendation that the condition be specifically considered in a periodic health examination. C. There is poor evidence regarding the inclusion or exclusion of the condition in a periodic health examination, but recommendations may be made on other grounds. D. There is fair evidence to support the recommendation that the condition not be considered in a periodic health examination. E. There is good evidence to support the recommendation that the condition be excluded from consideration in a periodic health examination.
DIETARY AND LIFESTYLE CHANGES
There has been no evidence to prove the effectiveness of dietary changes on relieving NVP symptoms. Advice for women suffering from NVP has traditionally revolved around dietary changes. Recommendations have included separating solids and liquids; eating small, frequent meals consisting of bland foods; avoiding fatty foods such as potato chips; and avoiding drinking cold, tart, or sweet beverages. Other advice has been to avoid sensory stimuli, particularly strong odours. Women alter their dietary habits to eat small frequent meals, to tolerate the NVP. This makes a randomized controlled trial (RCT) of these habits very difficult to perform. There is no evidence that short-term dietary deficiencies during the early weeks of pregnancy will have long-term consequences on pregnancy outcome. The use of vitamin supplements (including B-complex) is encouraged during pregnancy, and even if the woman is unable to tolerate her prenatal vitamin, it is important to maintain folic acid supplementation until the embryo's neural tube has closed. Caution is warranted with diets containing supra-pharmacological doses of individual vitamins, given the paucity of data regarding their safety for the fetus.
Sleep requirements increase in early pregnancy. 9 Because fatigue seems to exacerbate NVP, women should be encouraged to increase their rest, especially while they are symptomatic. It would seem appropriate for health care providers to adopt a liberal attitude toward providing leaves-of-absence from work. Such a policy should ultimately shorten the number of days lost from work.
Enlisting the support and understanding of close friends and family as well as supportive counselling may be of benefit to the woman suffering from NVP. 
NON-PHARMACOLOGICAL THERAPIES GINGER
Ginger (Zingiber officinale) is present as a spice in foods and beverages. It can also be taken in the form of tea or tablet extracts. There is only one RCT examining the efficacy, but not the safety, of 1000 mg/day of ginger. 10 Ginger is a nonregulated food product and most preparations available are of uncertain purity and composition. No evidence-based studies have been published to exclude the possibility of teratogenicity, and at the present time, large quantities of ginger should not be recommended as a treatment for NVP.
ACUPUNCTURE AND ACUPRESSURE
Stimulation of the P6 (Neiguan) point, located three-fingers' breadth proximal to the wrist, has been used for thousands of years by acupuncturists to treat nausea and vomiting from a variety of causes. Though there are no theoretical concerns about the safety of acupressure in pregnancy, efficacy of P6 acupressure is difficult to prove because it is impossible to perform a true double-blind trial compared with no intervention. Nonetheless, non-blinded RCTs have demonstrated a decrease in "persisting nausea" by at least 50%. 11 Bands worn on the wrist to apply acupressure may also be helpful. 11
RECOMMENDATION
2. Alternative therapies, such as ginger supplementation, acupuncture, and acupressure, may be beneficial. (I-A)
PHARMACOLOGICAL THERAPIES
When conservative measures have not been effective, pharmacological intervention is warranted. Treatment should start as soon as possible after the diagnosis of NVP. Included in this guideline is an evidence-based algorithm for nausea and vomiting of pregnancy, developed from evidence-based material on the safety and efficacy of available medications. 12 Therapies will be discussed in the same order as they appear in the algorithm.
ANTIHISTAMINES

DOXYLAMINE
Doxylamine is an H 1 receptor antagonist that has been shown to be effective in the treatment of NVP. It is currently marketed in Canada as a fixed combination of 10 mg doxylamine with 10 mg of pyridoxine (vitamin B 6 ), in a delayed-release formulation (Diclectin ® ). The standard recommended dose is up to four tablets a day, but recent data suggest that additional daily tablets (between 5 to 8 or up to 2.0 mg/kg) may be beneficial to address larger body size or suboptimally controlled symptoms. 13 A recent update of the Briggs' Drugs in Pregnancy and Lactation 14 revised the monograph of the product, and based on numerous studies on the safety and effectiveness of the doxylamine/pyridoxine-dicyclomine combination (previously marketed as Bendectin ® ) has changed the risk factor rating to "A," indicating that there is no risk to the fetus. 
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considered safe in pregnancy, with no human teratogenic potential. This conclusion is supported by a wide body of evidence and meta-analysis. 14 Data have actually shown a slightly reduced incidence of major and minor malformations with first trimester exposure to various antihistamines. 15 Pooled data from seven controlled trials looking at the effectiveness of various antihistamines for NVP indicate that these drugs are effective. 16 Availability in parenteral and suppository formulations makes these agents a good choice for treatment of acute or breakthrough episodes of NVP. Caution should be taken to avoid excessive dosing of H 1 receptor antagonists by combining different antihistamines in therapy. 
VITAMINS
PYRIDOXINE
Pyridoxine, vitamin B 6 , has been proven to be non-teratogenic in combination with doxylamine. 17 A retrospective cohort study also concluded that pyridoxine monotherapy had no increased risk for major malformations. 16 The effectiveness of vitamin B 6 monotherapy versus placebo has been shown in two RCTs (75 mg/day and 30 mg/day orally). 14
RECOMMENDATION
Pyridoxine monotherapy supplementation may be considered as an adjuvant measure. (I-A)
DOPAMINE ANTAGONISTS
PHENOTHIAZINES
Like antihistamines, phenothiazines (i.e., chlorpromazine, perphenazine, prochlorperazine, promethazine, trifluoperazine) have also been proven safe for use in pregnancy. Prospective and retrospective cohort, case-control, and record-linkage studies of patients with exposure to various and multiple phenothiazines have failed to demonstrate an increased risk for major malformations. 16 Significant therapeutic effect was demonstrated by three RCTs of various phenothiazines versus placebo for the treatment of severe NVP. 16 
METOCLOPRAMIDE
Metoclopramide is an upper gastrointestinal motility stimulant. Since NVP is associated with gastric dysrhythmia, the use of metoclopramide is common in clinical practice in many countries. There are limited studies of its potential to cause teratogenesis, but information to date is reassuring; two recently published studies have confirmed that there is no association between the drug exposure during the first trimester and congenital malformations. 19, 20 No RCTs have been published to support the effectiveness of metoclopramide in the treatment of NVP. An observational study using home subcutaneous therapy for HG suggested that metoclopramide is effective, safe, and economical. 21 
RECOMMENDATION
7.
Metoclopramide is safe to be used for management of NVP, although evidence for efficacy is more limited.
(II-2D) SEROTONIN 
5-HT 3 ANTAGONISTS
Limited data are available on 5-HT 3 antagonist safety. No malformations were reported in three case reports of exposure in pregnancy. 16 One RCT of 15 first trimester exposures demonstrated no increased risk of malformation. 16 
ONDANSETRON
Limited evidence is available on the effectiveness of ondansetron for NVP. Intravenous ondansetron did not demonstrate a therapeutic benefit over promethazine in one trial for the treatment of HG. 16 Ondansetron is also significantly more expensive per dose than promethazine. In general, 5-HT 3 antagonists may be safe to use during the first trimester, but the data are scant. Because of their limited effectiveness, they should not be advocated for first-line use until agents with established safety and effectiveness have been tried and have failed.
CORTICOSTEROIDS
Recent case-control studies revealed a small but significantly increased risk of oral clefting associated with first trimester exposure to corticosteroids. 16 However, the data on effectiveness are weak. Although a few controlled studies showed some effectiveness, 22 pooled results of those studies comparing corticotropin to placebo and methylprednisolone to promethazine in HG women failed to show a reduction in the number of subsequent re-admissions to hospital compared with controls. 16 In addition, corticotropin was not found to be superior to placebo based on "severity" or "relief" scores. 16, 22 Until more data are available, corticosteroids should be kept as the last line of therapy under ten weeks' gestation, and only when maternal benefits outweigh fetal risk. 
